The ProShare Advisors LLC Reduces Position in Gilead Sciences, Inc. (GILD)

The ProShare Advisors LLC Reduces Position in Gilead Sciences, Inc. (GILD)

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Violich Capital Management Inc. increased its position in Gilead Sciences by 1.2% in the third quarter. Violich Capital Management Inc. now owns 75,980 shares of the biopharmaceutical company’s stock worth $6,012,000 after buying an additional 900 shares during the period. Dubuque Bank & Trust Co. boosted its stake in Gilead Sciences by 6.6% in the third quarter. Dubuque Bank & Trust Co. now owns 60,698 shares of the biopharmaceutical company’s stock worth $4,802,000 after buying an additional 3,733 shares in the last quarter. Sector Gamma AS purchased a new stake in Gilead Sciences during the third quarter worth approximately $27,009,000. Boston Partners boosted its stake in Gilead Sciences by 51.7% in the third quarter. Boston Partners now owns 9,855,682 shares of the biopharmaceutical company’s stock worth $779,781,000 after buying an additional 3,358,289 shares in the last quarter. Finally, Windsor Capital Management LLC purchased a new stake in Gilead Sciences during the third quarter worth approximately $644,000. 74.19% of the stock is currently owned by hedge funds and other institutional investors.

ProShare Advisors LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% during the first quarter, Holdings Channel reports. The institutional investor owned 850,973 shares of the biopharmaceutical company’s stock after selling 34,236 shares during the period. ProShare Advisors LLC’s holdings in Gilead Sciences were worth $57,798,000 as of its most recent filing with the SEC.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at 65.40 on Monday. The company has a market cap of $85.46 billion, a price-to-earnings ratio of 6.91 and a beta of 1.11. Gilead Sciences, Inc. has a one year low of $63.88 and a one year high of $88.85. The stock has a 50 day moving average of $66.21 and a 200-day moving average of $69.90.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.18 by $0.02. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.66 billion. Gilead Sciences had a net margin of 44.43% and a return on equity of 92.36%. On average, equities analysts predict that Gilead Sciences, Inc. will post $8.21 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 29th. Stockholders of record on Friday, June 16th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Wednesday, June 14th. Gilead Sciences’s payout ratio is presently 18.91%. A number of research firms recently commented on GILD. ValuEngine cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 target price for the company. in a report on Tuesday, April 25th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 3rd. Barclays PLC reiterated an “overweight” rating and set a $85.00 target price on shares of Gilead Sciences in a report on Wednesday, May 3rd. Finally, BMO Capital Markets reiterated a “hold” rating and set a $76.00 target price (up previously from $75.00) on shares of Gilead Sciences in a report on Wednesday, May 3rd. Twelve research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $80.61.

In other Gilead Sciences news, Director John Francis Cogan sold 9,943 shares of the stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $67.25, for a total transaction of $668,666.75. Following the transaction, the director now directly owns 47,562 shares in the company, valued at approximately $3,198,544.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $67.18, for a total transaction of $4,926,510.94. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at $214,973,917.42. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 88,276 shares of company stock worth $5,932,578. Company insiders own 1.40% of the company’s stock. About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:GILD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD). Receive News & Ratings for Gilead Sciences Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gilead Sciences Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Related posts

Leave a Comment